Cedax

Selected form

Ceftibuten

Method of action: Bactericidal

Treatment option: Bronchitis, Gastroenteritis, Influenza, Infection, Middle Ear Infection, Fever, COPD,Acute, Acute Bronchitis, Pneumonia, Rheumatic Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cedax

Quick Facts

Property	Description
Active ingredient	Ceftibuten
Trade Name	Cedax (Prescription-Only Medicine - Rx)
Form	Capsules, Oral Suspension (often cherry flavored)
Pharmacological class	Third-generation cephalosporin antibiotic
General purpose	Anti-infective agent (bactericidal)
Origin	Synthetic (semisynthetic)

Classification and Differentiating Features

The medicine Cedax is the trade name for the active ingredient Ceftibuten, a synthetic antimicrobial drug classified as a third-generation cephalosporin antibiotic for oral administration. This class of antibiotic belongs to the broader beta-lactam antibiotic family, which is clinically recognized for its potent action against bacterial pathogens.

A differentiating feature of Ceftibuten is its high stability against certain bacterial defense enzymes known as beta-lactamases, which can inactivate older antibiotics. Pharmacological studies support its role as a bactericidal agent, meaning it actively kills susceptible bacteria rather than merely inhibiting their growth. This stability and mechanism make it a reliable choice for systemic anti-infective therapy.

Available Forms and General Anti-Infective Purpose

Ceftibuten is available as a single-ingredient product in two primary pharmaceutical preparations: capsules and a powder for oral suspension. Both forms are designed for systemic absorption following oral administration.

The Oral Suspension formulation of Cedax is often cherry flavored and specifically designed for ease of use in pediatric patients who may be unable to swallow the solid capsule form. The general purpose of this medicine is to leverage its potent anti-infective action. Its mechanism works by targeting and disrupting the synthesis of the bacterial cell wall, which is essential for the pathogen's survival.

Regulatory References

Ceftibuten: MedlinePlus Drug Information

What side effects are possible with Cedax?

Possible Side Effects and Safety Information

Cedax (ceftibuten) is an oral cephalosporin antibiotic. Its use is associated with a range of possible side effects, primarily affecting the gastrointestinal system.

Adverse Reaction Category	Common (1%–10% Incidence)	Clinically Significant/Serious (Postmarketing Reports)
Gastrointestinal	Diarrhea, Nausea, Vomiting, Dyspepsia, Abdominal pain	Clostridium difficile-associated diarrhea (CDAD) (can be severe), Melena (black, tarry stools)
Nervous System	Headache, Dizziness	Seizures (particularly with unadjusted doses in renal impairment), Psychosis, Aphasia
Hepatic & Renal	Increased ALT, Increased Bilirubin, Increased BUN	Jaundice, Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis)
Dermatologic	Rash, Urticaria, Pruritus	Anaphylaxis and other severe hypersensitivity reactions (a cephalosporin class risk)

Safety Considerations and Limitations

Hypersensitivity: Cedax is contraindicated in individuals with a known allergy to ceftibuten or the cephalosporin class of antibiotics. Caution is required due to potential cross-sensitivity in patients with a history of penicillin allergy.
Renal Function: Since the drug is significantly eliminated by the kidneys, dosage adjustment is mandatory for patients with renal impairment to prevent drug accumulation and potential toxicity, including the risk of seizures.
Gastrointestinal Risk: Use with caution in patients who have a history of gastrointestinal disease, especially colitis, as treatment may exacerbate these conditions or lead to superinfection or CDAD.
Population Specific: Safety and efficacy have not been established in infants younger than six months of age. The oral suspension contains sucrose, a relevant consideration for diabetic patients.
Monitoring Notes: Laboratory abnormalities reported include increases in blood urea nitrogen (BUN), creatinine, eosinophils, and liver enzymes (ALT/AST), as well as decreases in hemoglobin and changes in platelet/leukocyte counts.

Overdose and Emergency Response

The official regulatory documentation for Cedax (Ceftibuten) establishes the overdose profile through specific documented manifestations and non-negotiable emergency actions. All information is derived strictly from government regulatory sources.

Official Overdose Manifestations
Documented Sign	Seizures (Convulsions) are listed as a specific clinical manifestation of overdose.
Severe Outcome Signs	Collapse, trouble breathing, or inability to be awakened (unresponsiveness) are documented signs requiring immediate urgent medical attention.

In any suspected overdose, the official regulatory requirement is to contact the Poison Control helpline (1-800-222-1222). For critical, life-threatening presentations, including severe respiratory distress or collapse, immediate contact with emergency services (911) is mandated.

Specific procedural considerations for managing severe systemic exposure are documented. The drug is known to be removable by hemodialysis, a procedure capable of removing approximately 65% of the drug from the blood, serving as a supportive measure for extreme toxicity. No specific antidote is known to be documented in regulatory labeling. The risk of toxicity is heightened for the population with renal dysfunction, where the drug's clearance decreases proportionately, leading to increased plasma concentrations and requiring cautious management.

Therapeutic Uses of Cedax

What Cedax Treats: Main Uses and Benefits

Cedax, the brand name for the antibiotic ceftibuten, is a third-generation cephalosporin used to manage specific bacterial infections. It works by interfering with the formation of the bacterial cell wall, which eventually leads to the death of the susceptible bacteria. Because it targets bacteria specifically, it is not effective against viral infections such as the common cold or the flu.

Approved Indications

Cedax is primarily prescribed for mild to moderate infections involving the respiratory tract and the urinary system. Common applications include:

Acute Bronchitis: It is used to treat bacterial flare-ups in patients with chronic bronchitis when caused by susceptible strains of bacteria.
Acute Otitis Media: It helps manage middle ear infections in pediatric patients.
Pharyngitis and Tonsillitis: It is indicated for the treatment of throat and tonsil infections, typically those caused by Streptococcus pyogenes.
Urinary Tract Infections (UTIs): It is used for both uncomplicated and complicated infections of the urinary tract.

Mechanism of Action

As a beta-lactam antibiotic, ceftibuten binds to specific proteins within the bacterial cell wall. This binding inhibits the final stage of cell wall synthesis. Without a stable wall, the internal pressure of the bacterium causes it to rupture. Ceftibuten is designed to be stable against many beta-lactamases, which are enzymes produced by some bacteria to resist antibiotic treatment.

Benefits in Clinical Use

Broad-Spectrum Activity: Cedax is effective against a variety of Gram-negative and some Gram-positive bacteria, making it a versatile option for common community-acquired infections.
Stability: Its chemical structure allows it to remain active even in the presence of certain bacterial defense mechanisms that deactivate older penicillins or cephalosporins.
Targeted Therapy: By addressing the underlying bacterial cause of symptoms like inflammation, ear pain, or respiratory distress, it helps resolve the infection and prevents potential complications associated with untreated bacterial growth.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility criteria for using Cedax (Ceftibuten) are strictly defined by regulatory guidelines.

Populations for Whom Use is Established

Use is permitted for adults, teenagers, and children aged 6 months up to 12 years. However, the safety and efficacy of the medicine are not established in infants under 6 months of age.

Absolute Contraindications

Cedax must not be used by individuals with a known allergy to Ceftibuten or to any antibiotic in the cephalosporin class. Use is also contraindicated when co-administering certain live bacterial vaccines, including BCG, Typhoid, and Cholera vaccines.

Eligibility Restrictions

Conditional use is defined by health status. Patients with renal impairment must use the medicine with caution and require professional management, as the drug's clearance is reduced. Caution is also advised for those with a history of colitis or severe diarrhea. For diabetic patients, the oral suspension formulation presents a restriction due to its sucrose content. During pregnancy, the medicine is classified as Category B and should only be used if clearly necessary. Use in nursing mothers requires careful assessment due to unknown excretion levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official prescribing information for Ceftibuten (Cedax) documents specific interaction patterns with other products, focused on effects on drug exposure, required timing separation, and formal combination restrictions.

Exposure and Pharmacodynamic Effects

Co-administration with Probenecid may increase the body's exposure to Ceftibuten by inhibiting its renal clearance. Other agents, such as the histamine H2-receptor antagonist Ranitidine, have been shown to increase Ceftibuten's peak plasma concentration and overall exposure. Pharmacodynamic interactions include a documented risk of the anticoagulant effect being increased when combined with Vitamin K Antagonists (e.g., Warfarin). Use with Aminoglycosides carries a risk of increased nephrotoxic effects. Additionally, the drug may interfere with laboratory procedures such as the Direct Coombs’ test.

Contraindicated Combinations and Timing Rules

Due to the risk of therapeutic antagonism, the use of Ceftibuten is formally avoided or restricted with live bacterial vaccines (such as BCG and Cholera vaccine strains) and live Fecal Microbiota preparations, as the antibiotic action may decrease their effectiveness. For the oral suspension formulation, food may reduce absorption, necessitating administration on an empty stomach. Products containing Zinc may interfere with absorption and must be separated from the Ceftibuten dose by at least three hours. In patients with renal impairment, slower clearance of Ceftibuten may lead to increased exposure.

Mechanism of Action

Molecular Targeting of Bacterial Cell Wall Construction

The mechanism of action for Ceftibuten is defined by its ability to act as a decoy and irreversibly inhibit essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). These enzymes are crucial for the final cross-linking step of the peptidoglycan layer, which forms the structural backbone of the bacterial cell wall. By binding covalently to the PBP active site, the drug immediately halts the assembly of the cell wall structure.

Initiating Bactericidal Lysis

The structural failure resulting from PBP inhibition initiates a mechanistic cascade that leads to bacterial destruction. The weakened cell wall can no longer withstand the high internal osmotic pressure, leading to rupture (lysis) of the cell membrane. This destructive process is combined with the effects of dysregulated bacterial enzymes (autolysins), resulting in the irreversible bactericidal (killing) action against the susceptible pathogen.

Constraints on the Mechanistic Scope

The action of this bactericidal mechanism is constrained by microbial resistance factors. Certain bacteria produce β-lactamase enzymes that chemically destroy the drug before it reaches the PBP target, overriding the mechanism entirely. Evasion also occurs when pathogens alter the molecular structure of the PBPs themselves, reducing the drug’s binding affinity and thereby restricting the mechanistic interaction.

Dosage and Administration Information

How to Use Cedax

Cedax, which contains the active ingredient ceftibuten, is strictly an oral medication, meaning it is administered by mouth and is not available for intravenous or intramuscular use. The medicine is provided in two primary forms: capsules and a powder for oral suspension. The dosing schedule is standardized as a single dose once daily (qDay) for the duration of the prescribed course, which is typically 10 days for common approved infections.

Administration and Dosage Regimens

The standard adult dose is 400 mg once daily. For children between 6 months and 11 years, the dose is determined by weight at 9 mg/kg per day, with the total daily dose not to exceed 400 mg. Safety and usage have not been established in infants younger than 6 months of age.

Dosing Context	Official Labeled Regimen	Duration Pattern
Standard Adult Dose	400 mg once daily	Typically 10 days
Pediatric Dose	9 mg/kg once daily (max 400 mg)	Typically 10 days

Administration Timing and Special Conditions

Proper administration involves specific timing relative to food, particularly for the liquid formulation. The oral suspension must be taken on an empty stomach, specifically at least 2 hours before a meal or 1 hour after a meal, to ensure optimal absorption. While the capsules may be taken without strict regard to food, absorption is optimized when taken without food.

Mandatory dose adjustments are required for patients with reduced kidney function (renal impairment). For instance, the dose is reduced to 200 mg once daily when the creatinine clearance is between 30 and 49 mL/min. For patients undergoing hemodialysis, the full dose is administered once the dialysis session is complete.

Recent Clinical Evidence

Research evidence / Overview of studies for Cedax

Evidence for Acute Otitis Media (AOM) and Throat Infections

The evidence base for Ceftibuten in treating Acute Otitis Media (AOM), an ear infection, and Pharyngitis/Tonsillitis is primarily derived from Randomized Controlled Trials (RCTs) and systematic reviews. For both conditions, the research was conducted during periods of increased symptom activity in the observed populations. Researchers explored short-term symptom changes and studies monitored two main outcomes: clinical cure (the resolution of physical signs and patient-reported outcomes describing perceived discomfort) and bacteriological eradication (the elimination of the specific bacteria causing the infection).

For AOM, the studies were conducted mostly in pediatric populations. Studies included monitoring the drug’s processing in the body. For streptococcal throat infections, trials compared Ceftibuten against standard therapies, and the findings describe patterns observed in both the changes in symptoms and the rate of bacterial findings. While these core trials provide important context, long-term effects are not fully established.

Evidence for Respiratory and Urinary Tract Infections

The research exploring the use of Ceftibuten for Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) in adults and Urinary Tract Infections (UTIs) relies on comparative clinical trials. For ABECB, studies monitored outcomes related to physical discomfort and systemic or functional imbalance, specifically looking for clinical cure or improvement and bacteriological eradication of pathogens in adults. In the case of UTIs, research explored short-term changes in patient-reported outcomes, and data show patterns related to drug concentration in the urine, which was studied for treating this type of infection. However, data for certain groups remain insufficient.

What is Still Uncertain About the Research for Cedax

A key limitation of the available evidence is that certainty remains low for some aspects of the drug's use, particularly in complicated infections in adult populations. For example, there is no global consensus regarding the use of oral beta-lactam antibiotics like Ceftibuten in treating specific severe adult UTIs like pyelonephritis, where comparative evidence is lacking. Furthermore, trial heterogeneity in defining patient groups means that cross-study comparisons can be complex. Finally, while findings describe group patterns, not personal outcomes, the evidence is limited regarding the use of the drug in patients with severe underlying conditions or various comorbidities.

Key Studies & References Short- vs. Long-Course Antibiotic Treatment for Acute Streptococcal Pharyngitis: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Cedax (FAQ)

Q: Is Cedax a type of cephalosporin?

A: Cedax contains the active ingredient ceftibuten, which is officially classified as a third-generation cephalosporin antibiotic. This drug belongs to a class of antibiotics that work by targeting the bacterial cell wall and are often used to treat a wide range of bacterial infections.

Q: Can I take Cedax with acid reflux medication?

A: Official prescribing information mentions an interaction where a drug like Ranitidine (a type of H2-receptor antagonist used for acid reflux) has been shown to increase the concentration of ceftibuten in the body. This indicates a documented pharmacokinetic change described in the drug's regulatory profile.

Q: Are there any specific foods to avoid while taking Cedax?

A: Regulatory instructions for the oral suspension are specific: it must be taken on an empty stomach, meaning at least two hours before a meal or one hour after a meal. This timing requirement is set to optimize drug absorption. The capsule form, however, may be taken without such strict regard to food.

Q: Are there restrictions on who can use Cedax?

A: Official warnings advise on restrictions, including the potential for serious hypersensitivity (allergic) reactions in patients sensitive to beta-lactam drugs. Use has not been established in infants younger than six months. Additionally, dosage adjustments are required for individuals with reduced kidney function.

Q: What conditions make someone ineligible to take Cedax?

A: Official warnings highlight the risk of serious allergic reactions, especially in patients with a history of penicillin sensitivity. Infants under six months of age are ineligible as safety and efficacy have not been established in that population.

Q: What is the maximum duration of treatment officially studied for Cedax?

A: Official prescribing documents typically list the duration of treatment, with the standard regimen for approved infections being 10 days. This regimen is the standard duration established in clinical trials for many common infections.

Q: Can I take other antibiotics with Cedax?

A: The regulatory interaction profile mentions that combining Cephalosporins (like ceftibuten) with other antibiotics, specifically Aminoglycosides, may increase nephrotoxic effects (affecting kidney function). Additionally, there is a risk of therapeutic antagonism with certain other beta-lactam drugs.

Q: What is the main reason Cedax is prescribed?

A: According to official product information, Cedax is a prescription medicine used to treat a wide variety of bacterial infections. It is officially indicated for treating infections in areas such as the upper and lower respiratory tract and the urinary tract.

Q: What conditions does Cedax treat?

A: Studies and official information indicate that Cedax is used to treat infections caused by susceptible bacteria. These typically include infections of the upper and lower respiratory tract (like pharyngitis and bronchitis) and various urinary tract infections.

Q: Does Cedax treat bacterial infections only?

A: Official regulatory information states that this medicine is used to treat bacterial infections and will not work for colds, flu, or other virus infections. The FDA label states that its use is intended for infections proven or strongly suspected to be caused by bacteria.

Q: How long does it typically take for Cedax to start working?

A: Pharmacokinetic data described in regulatory documents indicates that the concentration of the active drug component in the blood typically reaches its peak (Cmax) around two to three hours after a dose is administered. This measurement indicates when the drug reaches its highest concentration in the bloodstream.

Q: How quickly does Cedax leave the body?

A: According to official pharmacokinetic studies, the mean terminal half-life of the active drug component in healthy adults is approximately 2.4 hours. The half-life is the amount of time it takes for the amount of drug in the body to be reduced by half.

Q: What happens if I miss a dose of Cedax?

A: Regulatory consumer information states that a missed dose is generally taken as soon as it is remembered. However, if the time for the next scheduled dose is near, the missed dose is typically skipped.

Q: Can Cedax cause a metallic taste in the mouth?

A: Taste perversion (dysgeusia, an unusual taste) is listed in official adverse event reports. Regulatory data classifies this as an uncommon side effect, occurring in less than 1% of patients in clinical trials.

Q: Is feeling tired a common side effect of Cedax?

A: Fatigue and drowsiness (somnolence) are noted in the regulatory list of adverse events. These effects are considered uncommon, occurring in less than 1% of patients in clinical studies.

Q: Can Cedax cause diarrhea or stomach upset?

A: Diarrhea, nausea, and stomach upset (dyspepsia) are listed as common adverse reactions in official prescribing information. These effects occurred in 1% to 10% of patients during clinical trials.

Q: Are there any serious side effects associated with Cedax?

A: The official label includes serious warnings about the potential for severe hypersensitivity (allergic) reactions, which can be life-threatening. There is also a documented risk of developing Clostridioides difficile-associated diarrhea (CDAD) with its use.

Q: Does alcohol interact with Cedax?

A: Official regulatory interaction information indicates that alcohol interactions are recognized for ceftibuten, and details are provided within the drug's consumer warnings.

Q: Is it safe to drive while taking Cedax?

A: The adverse event profile lists central nervous system effects such as dizziness and drowsiness (somnolence). The effects could potentially impair the ability to safely operate a vehicle or machinery.

Q: Can older adults use Cedax?

A: The drug has been included in studies involving elderly patients (65 years of age and older). Official information states that dosage adjustment may be necessary in older adults, particularly those with reduced kidney function (renal impairment).

Q: Is Cedax safe to use during pregnancy?

A: The FDA classifies this drug as Pregnancy Category B. Regulatory text states that the drug is to be used during pregnancy only if clearly needed, citing a lack of controlled data from human pregnancies.

Q: Can I use Cedax while breastfeeding?

A: Regulatory warnings state that the drug is excreted into human milk in small amounts. Official information states that caution is warranted when this drug is administered to a nursing woman.

Q: What research supports the use of Cedax for ear infections?

A: Efficacy has been documented in clinical trials for the treatment of various infections, including acute otitis media (middle ear infection). Pharmacokinetic studies have also confirmed that the drug penetrates into middle-ear fluid.

Q: What is the difference between an allergy and a side effect to Cedax?

A: The official label distinguishes between common adverse events (side effects) and serious hypersensitivity (allergic) reactions. Allergic reactions like anaphylaxis involve a severe immune response and are highlighted as serious warnings, being more likely in individuals with a known sensitivity.

Q: Can Cedax cause a yeast infection?

A: Moniliasis (candidiasis, a yeast infection) and vaginitis (vaginal inflammation or discharge) are listed in official regulatory documents. These effects are classified as uncommon adverse events.

Q: What should I do if I notice a skin rash after starting Cedax?

A: Rash and pruritus (itching) are classified as uncommon side effects. However, severe skin reactions, such as Stevens-Johnson syndrome, have been reported post-marketing, which are highlighted as medical emergencies in official warnings.

Q: Does taking Cedax make birth control less effective?

A: Regulatory interaction data indicates that certain antibiotics, including ceftibuten, may reduce the effects of ethinyl estradiol. This is a component in many oral contraceptives and the interaction could potentially increase the risk of pregnancy.

Q: Is it normal to feel dizzy or lightheaded while on Cedax?

A: Dizziness is listed as a common adverse event in the regulatory adverse reaction section. This means that in clinical trials, this effect occurred in between 1% and 10% of patients.

Q: What is the recommended storage temperature for Cedax?

A: Official information states that the capsules should be stored in a closed container at room temperature. The oral liquid (suspension) must be stored in the refrigerator, and any unused portion must be disposed of after 14 days.

Q: What types of bacteria is Cedax designed to fight?

A: Regulatory microbiology data indicates that the drug has a broad spectrum of activity against many types of bacteria. This includes many gram-negative organisms and selected gram-positive organisms, such as Haemophilus influenzae.

Q: How long after finishing the prescription is Cedax still in my system?

A: Based on the pharmacokinetic half-life of approximately 2.4 hours, the drug is considered to be mostly eliminated from the body after about five to six half-lives following the last dose.

Q: Why must the entire course of Cedax be finished?

A: Official warnings state that discontinuation of the medication earlier than prescribed may lead to the development of drug-resistant bacteria or increase the risk of a second infection (superinfection).

Q: Is there a risk of developing C. difficile infection with Cedax?

A: The risk of Clostridioides difficile-associated diarrhea (CDAD) is listed as an important warning in the official label. This risk has been reported with the use of nearly all antibacterial agents, including those in the cephalosporin class.

Q: Can Cedax make certain vaccines less effective?

A: Regulatory interaction data indicates that ceftibuten is listed as having serious interactions with certain live vaccines. This includes the BCG vaccine live, cholera vaccine, and typhoid vaccine live.

Q: What are the official warnings listed for Cedax?

A: Official regulatory documents list several important warnings. These include the potential for serious allergic reactions (Anaphylaxis), Clostridioides difficile-Associated Diarrhea (CDAD), and the potential for microbial overgrowth in the body.

Q: Is Cedax used for prevention or just treatment of infections?

A: Official information describes the drug’s purpose as being used for the treatment of bacterial infections. The FDA label states that it is intended for use against infections that are proven or strongly suspected to be caused by bacteria.

Q: What research has been done on Cedax for respiratory infections?

A: Efficacy for the treatment of infections has been documented in clinical trials involving both adults and children. These studies specifically addressed upper and lower respiratory tract infections such as pharyngitis, sinusitis, and bronchitis.

Q: Does Cedax affect blood sugar levels?

A: Official warnings advise that the oral suspension formulation contains sucrose (sugar). Additionally, the drug may interfere with certain urine glucose tests, which could potentially cause a false result.

Q: Is a severe allergic reaction to Cedax common?

A: The label reports serious and occasionally fatal hypersensitivity (allergic) reactions. These events are officially stated to be more likely in individuals with a history of sensitivity to beta-lactam drugs like penicillins.

Q: Why do doctors ask about previous allergies before prescribing Cedax?

A: Official warnings advise healthcare providers to inquire about prior hypersensitivity reactions to penicillins, cephalosporins, or other allergens before starting therapy. This is due to the potential risk of a severe allergic cross-reaction.

How should Cedax be stored and disposed of?

How to Store and Dispose of Cedax (Ceftibuten)

The storage conditions for Ceftibuten are dependent on the specific dosage form, as outlined in official regulatory labeling.

Storage Requirements

Dosage Form	Required Storage Conditions	Stability Constraint
Capsules / Unmixed Powder	Store between 2 C and 25 C (36 F and 77 F). Keep away from light and moisture.	Keep from freezing.
Reconstituted Suspension	Store in the refrigerator (2 C to 8 C / 36 F to 46 F). Keep container tightly closed.	Discard any unused portion after 14 days of reconstitution. Do not freeze.

All forms of this medicine must be kept out of the reach of children and pets.

Disposal Instructions

Official disposal guidance recommends utilizing a drug take-back program for unused or expired Ceftibuten. The product is not on the FDA's flush list and must not be poured down a sink or toilet. If a take-back option is unavailable, the unused medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.